Physician profile
Roberto Alejandro Hernando
NPI 1811985708
$13,875.96
in general payments reported to CMS, 2019-2025
24 companies · $2,284 in 2025
The $2,284 reported for 2025 was more than what 90% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,332 · 2020: $1,551 · 2021: $3,023 · 2022: $1,489 · 2023: $1,805 · 2024: $2,390 · 2025: $2,284.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,371 · Education: $109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,370.75 |
| Education | $109.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $1,637.91 | 2019-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $1,448.41 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Lundbeck LLC | $1,353.00 | 2019-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $1,234.55 | 2019-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,132.79 | 2021-2025 | Caplyta |
| Abbvie INC. | $1,075.93 | 2021-2025 | |
| Alkermes, INC. | $1,071.16 | 2019-2025 | Aristada, Lybalvi |
| Sunovion Pharmaceuticals INC. | $837.69 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $746.34 | 2019-2025 | Invega Sustenna, Spravato |
| Neurocrine Biosciences, INC. | $724.04 | 2020-2025 | Ingrezza |
| Allergan, INC. | $641.90 | 2019-2020 | |
| Almatica Pharma LLC | $576.18 | 2021-2025 | Loreev Xr, Sertraline Hcl, Citalopram |
| Vanda Pharmaceuticals INC. | $518.31 | 2020-2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $240.11 | 2023-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $164.85 | 2024-2025 | Cobenfy |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $120.54 | 2019-2023 | Aplenzin |
| Indivior INC. | $79.09 | 2023-2024 | Perseris |
| Merck Sharp & Dohme LLC | $71.79 | 2020-2021 | |
| Shire North American Group INC | $59.55 | 2019 | |
| Tris Pharma INC | $41.92 | 2024 | Dyanavel Xr |
| Neos Therapeutics, Lp | $30.66 | 2025 | Exxua |
| Luye Pharma (USA) Ltd. | $24.34 | 2025 | Erzofri Extended-Release |
| Tempus Ai, INC | $22.59 | 2024 | |
| Livanova USA, INC. | $22.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roberto Hernando listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.